Khorana Risk Score for Thrombosis Prediction in Patients with Gynecologic Malignancies Using Immune Checkpoint Inhibitors- a Real-World Validation

被引：0
|
作者：
Song, Junmin [1 ]
Chang, Yu-Cheng [2 ]
Abram, Ana Maria Diaz [1 ]
Ahn, Jaeun [3 ]
Chi, Kuan-Yu [1 ]
Chang, Yu [4 ]
Chiang, Cho-Han [5 ]
机构：
[1] Albert Einstein Coll Med, Jacobi Med Ctr, Dept Med, Bronx, NY 10461 USA
[2] Danbury Hosp, Dept Med, Danbury, CT USA
[3] Eastern Virginia Med Sch, Dept Internal Med, Norfolk, VA USA
[4] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg,Sect Neurosurg, Tainan, Taiwan
[5] Harvard Med Sch, Mt Auburn Hosp, Dept Med, Cambridge, MA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-212175
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5582 / 5583
页数：2
相关论文
共 50 条
  • [41] The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population
    Sattar, Joobin
    Kartolo, Adi
    Hopman, Wilma M.
    Lakoff, Joshua Matthew
    Baetz, Tara
    JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (03) : 411 - 414
  • [42] Real-world cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study
    Zhang, Chuan
    Chen, Zhulu
    Mo, Chunhua
    Gao, Diansha
    Zhu, Yuxi
    Qin, Shu
    Zuo, Zhong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (12): : 6074 - +
  • [43] Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database
    Fan, Qianqian
    Chen, Huan
    Hu, Yang
    Zhao, Bin
    CUTANEOUS AND OCULAR TOXICOLOGY, 2023, 42 (02) : 68 - 73
  • [44] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Kang Chen
    Wei Wei
    Lei Liu
    Zhu-Jian Deng
    Le Li
    Xiu-Mei Liang
    Ping-Ping Guo
    Lu-Nan Qi
    Zhi-Ming Zhang
    Wen-Feng Gong
    Shan Huang
    Wei-Ping Yuan
    Liang Ma
    Bang-De Xiang
    Le-Qun Li
    Jian-Hong Zhong
    Cancer Immunology, Immunotherapy, 2022, 71 : 1063 - 1074
  • [45] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Chen, Kang
    Wei, Wei
    Liu, Lei
    Deng, Zhu-Jian
    Li, Le
    Liang, Xiu-Mei
    Guo, Ping-Ping
    Qi, Lu-Nan
    Zhang, Zhi-Ming
    Gong, Wen-Feng
    Huang, Shan
    Yuan, Wei-Ping
    Ma, Liang
    Xiang, Bang-De
    Li, Le-Qun
    Zhong, Jian-Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1063 - 1074
  • [46] Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis
    Paderi, Agnese
    Gambale, Elisabetta
    Botteri, Cristina
    Giorgione, Roberta
    Lavacchi, Daniele
    Brugia, Marco
    Mazzoni, Francesca
    Giommoni, Elisa
    Bormioli, Susanna
    Amedei, Amedeo
    Pillozzi, Serena
    Matucci Cerinic, Marco
    Antonuzzo, Lorenzo
    MOLECULES, 2021, 26 (19):
  • [47] IMMUNE-RELATED ADVERSE EVENTS FROM IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A REAL-WORLD EXPERIENCE
    Gampa, Anuhya
    Peeraphatdit, Thoetchai
    Charlton, Michael R.
    Pillai, Anjana A.
    HEPATOLOGY, 2020, 72 : 694A - 695A
  • [48] Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
    Choi, Min Chul
    Moon, Yong Wha
    Jung, Sang Geun
    Park, Hyun
    Joo, Won Duk
    Song, Seung Hun
    Lee, Chan
    Kim, Gwangil
    Kim, Kyoung Ah
    YONSEI MEDICAL JOURNAL, 2020, 61 (10) : 844 - 850
  • [49] Real-world use of checkpoint inhibitors in the management of thoracic malignancies: a single-institution experience
    Lynch, J.
    Murias, C.
    Newsom-Davis, T.
    LUNG CANCER, 2017, 103 : S37 - S37
  • [50] Real-world evaluation of the efficacy of immune checkpoint inhibitors in the treatment of metastatic breast cancer
    Qian, Xiaoyan
    Tao, Yunxia
    Chen, Haizhu
    Li, Xin
    Wang, Yaqin
    Xu, Xiaoming
    Li, Shuo
    Chen, Haoyu
    Cang, Shundong
    Liu, Yang
    ONCOLOGY LETTERS, 2025, 29 (01)
12345